

# Rossella Paolini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1247163/publications.pdf>

Version: 2024-02-01

93  
papers

3,155  
citations

147801

31  
h-index

175258

52  
g-index

94  
all docs

94  
docs citations

94  
times ranked

4507  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phosphorylation and dephosphorylation of the high-affinity receptor for immunoglobulin E immediately after receptor engagement and disengagement. <i>Nature</i> , 1991, 353, 855-858.	27.8	280
2	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1442-1449.	1.6	167
3	NKG2D and Its Ligands: "One for All, All for One". <i>Frontiers in Immunology</i> , 2018, 9, 476.	4.8	165
4	3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells. <i>Scientific Reports</i> , 2017, 7, 1093.	3.3	130
5	Syk-dependent Phosphorylation of Shc. <i>Journal of Biological Chemistry</i> , 1996, 271, 16268-16272.	3.4	117
6	NK cells and interferons. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 113-120.	7.2	110
7	Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF- $\kappa$ B axis. <i>OncolImmunology</i> , 2017, 6, e1279372.	4.6	100
8	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. <i>Thrombosis and Haemostasis</i> , 2009, 101, 233-238.	3.4	85
9	Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. <i>Journal of Immunology</i> , 2015, 195, 736-748.	0.8	85
10	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 23609-23630.	1.8	78
11	Activation of Syk Tyrosine Kinase Is Required for c-Cbl-mediated Ubiquitination of Fc $\gamma$ RI and Syk in RBL Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 36940-36947.	3.4	73
12	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. <i>Journal of Hematology and Oncology</i> , 2016, 9, 134.	17.0	72
13	Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1677.	4.1	71
14	CD155: A Multi-Functional Molecule in Tumor Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 922.	4.1	58
15	Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. <i>BMC Cancer</i> , 2015, 15, 17.	2.6	54
16	Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 9611-9616.	7.1	52
17	Cutting Edge: Functional Role for Proline-Rich Tyrosine Kinase 2 in NK Cell-Mediated Natural Cytotoxicity. <i>Journal of Immunology</i> , 2000, 164, 2272-2276.	0.8	50
18	Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. <i>Science Signaling</i> , 2015, 8, ra108.	3.6	50

#	ARTICLE	IF	CITATIONS
19	Anti-CD20 Therapy Acts via Fc $\gamma$ RIIIA to Diminish Responsiveness of Human Natural Killer Cells. <i>Cancer Research</i> , 2015, 75, 4097-4108.	0.9	46
20	Regulation of NKG2D Expression and Signaling by Endocytosis. <i>Trends in Immunology</i> , 2016, 37, 790-802.	6.8	46
21	CIN85 Regulates the Ligand-Dependent Endocytosis of the IgE Receptor: A New Molecular Mechanism to Dampen Mast Cell Function. <i>Journal of Immunology</i> , 2005, 175, 4208-4216.	0.8	45
22	Hyperthyroidism as a Cause of Pulmonary Arterial Hypertension: A Prospective Study. <i>Angiology</i> , 2006, 57, 600-606.	1.8	44
23	Effects of cadmium on lymphocyte activation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1989, 1011, 25-32.	4.1	42
24	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	3.5	42
25	Obinutuzumab-mediated high-affinity ligation of Fc $\gamma$ RIIIA/CD16 primes NK cells for IFN $\gamma$ production. <i>Oncolmmunology</i> , 2017, 6, e1290037.	4.6	39
26	In vivo cadmium treatment alters natural killer activity and large granular lymphocyte number in the rat. <i>Immunopharmacology</i> , 1989, 18, 149-156.	2.0	38
27	Targeted therapy in severe asthma today: focus on immunoglobulin E. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1979-1987.	4.3	38
28	Regulation of Fc Receptor Endocytic Trafficking by Ubiquitination. <i>Frontiers in Immunology</i> , 2014, 5, 449.	4.8	37
29	Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). <i>American Journal of Hematology</i> , 2000, 65, 177-178.	4.1	36
30	câ€Cbl regulates MICAâ€Cbut not ULBP2â€Cinduced NKG2D downâ€Cmodulation in human NK cells. <i>European Journal of Immunology</i> , 2014, 44, 2761-2770.	2.9	35
31	Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. <i>Haematologica</i> , 2010, 95, 1230-1232.	3.5	33
32	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 881-887.	3.5	32
33	Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexateâ€Ccytarabine Combination. <i>Oncologist</i> , 2011, 16, 336-341.	3.7	30
34	p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. <i>Oncolmmunology</i> , 2017, 6, e1264564.	4.6	29
35	Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. <i>Scientific Reports</i> , 2017, 7, 10445.	3.3	29
36	Hashimoto's Thyroiditis and Graves' Disease Associated with Retroperitoneal Fibrosis. <i>Thyroid</i> , 2002, 12, 829-831.	4.5	28

#	ARTICLE	IF	CITATIONS
37	Lipid Raft-Dependent Fc $\mu$ RI Ubiquitination Regulates Receptor Endocytosis through the Action of Ubiquitin Binding Adaptors. <i>PLoS ONE</i> , 2009, 4, e5604.	2.5	28
38	Translating the anti-myeloma activity of Natural Killer cells into clinical application. <i>Cancer Treatment Reviews</i> , 2018, 70, 255-264.	7.7	28
39	The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing. <i>European Journal of Immunology</i> , 2019, 49, 873-883.	2.9	28
40	Effects of protein kinase C (PK-C) activators and inhibitors on human large granular lymphocytes (LGL): Role of PK-C on natural killer (NK) activity. <i>Cellular Immunology</i> , 1989, 118, 470-481.	3.0	27
41	PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway. <i>Blood</i> , 2012, 119, 2252-2262.	1.4	27
42	Interaction between Histidine-Rich Glycoprotein and Platelet Factor 4 with Dermatan Sulfate and Low-Molecular-Weight Dermatan Sulfate. <i>Angiology</i> , 1992, 43, 59-62.	1.8	23
43	Ubiquitination and endocytosis of the high affinity receptor for IgE. <i>Molecular Immunology</i> , 2010, 47, 2427-2434.	2.2	23
44	Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12176.	12.2	22
45	Tyrosine kinase-dependent ubiquitination of CD16 $\gamma$ subunit in human NK cells following receptor engagement. <i>European Journal of Immunology</i> , 1999, 29, 3179-3187.	2.9	21
46	Fc $\mu$ RI Signaling in the Modulation of Allergic Response: Role of Mast Cell-Derived Exosomes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5464.	4.1	21
47	Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF- $\kappa$ B Transcription Factor. <i>Cancers</i> , 2020, 12, 440.	3.7	21
48	The Adaptor Molecule CIN85 Regulates Syk Tyrosine Kinase Level by Activating the Ubiquitin-Proteasome Degradation Pathway. <i>Journal of Immunology</i> , 2007, 179, 2089-2096.	0.8	20
49	Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2019, 10, 2557.	4.8	20
50	Attenuation of PI3K/Akt-Mediated Tumorigenic Signals through PTEN Activation by DNA Vaccine-Induced Anti-ErbB2 Antibodies. <i>Journal of Immunology</i> , 2010, 184, 4170-4177.	0.8	19
51	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 289-293.	4.1	19
52	Activation of liver X receptor upregulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. <i>FASEB Journal</i> , 2019, 33, 9489-9504.	0.5	19
53	Defective expression of the T-cell receptor-CD3 $\gamma$ chain in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 201-208.	2.5	18
54	Immune complexes exposed on mast cell-derived nanovesicles amplify allergic inflammation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1260-1263.	5.7	18

#	ARTICLE	IF	CITATIONS
55	Negative signals from FcγRI engagement attenuate mast cell functions. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2007, 55, 219-229.	2.3	17
56	Syk-dependent regulation of Hrs phosphorylation and ubiquitination upon FcγRI engagement: Impact on Hrs membrane/cytosol localization. <i>European Journal of Immunology</i> , 2012, 42, 2744-2753.	2.9	16
57	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <i>American Journal of Hematology</i> , 2013, 88, 955-960.	4.1	14
58	Kinase Activation through the High-Affinity Receptor for Immunoglobulin E. <i>ImmunoMethods</i> , 1994, 4, 35-40.	0.8	13
59	Persistence of Tyrosine-phosphorylated FcγRI in Deactivated Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 15987-15992.	3.4	13
60	Splenomegaly as the First Manifestation of Thyroid Cancer Metastases. <i>Tumori</i> , 1997, 83, 779-782.	1.1	13
61	Co-existence of cutaneous T-cell lymphoma and B hairy cell leukemia. <i>American Journal of Hematology</i> , 2000, 64, 197-202.	4.1	13
62	Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. <i>Cell Death and Disease</i> , 2021, 12, 836.	6.3	13
63	Proliferative effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) and calcium ionophores on human large granular lymphocytes (LGL). <i>Cellular Immunology</i> , 1988, 113, 70-81.	3.0	12
64	SAMHD1 phosphorylation and cytoplasmic relocalization after human cytomegalovirus infection limits its antiviral activity. <i>PLoS Pathogens</i> , 2020, 16, e1008855.	4.7	12
65	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
66	B Non-Hodgkin's Lymphoma in a Haemophilia Patient with Idiopathic CD4+ T-lymphocytopenia. <i>Leukemia and Lymphoma</i> , 1996, 21, 177-180.	1.3	11
67	The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. <i>Cell Death and Disease</i> , 2019, 10, 324.	6.3	11
68	Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. <i>Tumor Biology</i> , 2017, 39, 101042831769432.	1.8	10
69	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	3.7	10
70	NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7859.	4.1	10
71	Remission of leukaemic meningitis after fludarabine. <i>Lancet, The</i> , 1995, 346, 972.	13.7	8
72	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	1.7	8

#	ARTICLE	IF	CITATIONS
73	Effects of Glycosaminoglycans and Protamine Chloridrate on Platelet Aggregation Induced by Collagen and Thrombin. <i>Angiology</i> , 1989, 40, 170-174.	1.8	7
74	Spontaneous evolution of essential thrombocythaemia into acute megakaryoblastic leukaemia with trisomy 8, trisomy 21 and cutaneous involvement. <i>European Journal of Haematology</i> , 2003, 71, 466-469.	2.2	7
75	Cbl Family Proteins: Balancing Fc&#949;RI-Mediated Mast Cell and Basophil Activation. <i>International Archives of Allergy and Immunology</i> , 2011, 156, 16-26.	2.1	7
76	Epstein-Barr Virusâ€“Positive Mucocutaneous Ulcer Mimicking Rectal Carcinoma at 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, 645-646.	1.3	7
77	Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia. <i>Oncotarget</i> , 2018, 9, 32219-32231.	1.8	6
78	Complex chromosomal rearrangements leading to <sc><i>MECOM</i></sc> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 375-388.	2.8	5
79	Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation. <i>European Journal of Immunology</i> , 2021, 51, 2607-2617.	2.9	5
80	Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 315-318.	1.0	4
81	Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 226-229.	0.8	4
82	Rituximab, bendamustine and cytarabine (Râ€“BAC) in patients with relapsedâ€“refractory aggressive Bâ€“cell lymphoma. <i>American Journal of Hematology</i> , 2018, 93, E386-E389.	4.1	4
83	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	2.7	4
84	Adhesion and activation molecules expressed by human natural killer cells. <i>Cytotechnology</i> , 1991, 5, 117-121.	1.6	3
85	Anti-hepatitis C virus serology in patients affected with congenital coagulation defects: A comparative study using three second generation ELISA tests. <i>Transfusion Science</i> , 1994, 15, 303-311.	0.6	2
86	Perinatal Intracranial Hemorrhage as First Manifestation of Congenital Hypofibrinogenemia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1996, 2, 60-63.	1.7	2
87	Pulmonary Hypertension and Systemic Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 459-467.	3.1	2
88	Response criteria for malignant lymphoma. <i>Nuclear Medicine Communications</i> , 2015, 36, 398-405.	1.1	1
89	Modulation of CD16 Antigen on NK Cells and Granulocytes by Protein Kinase C Activators and Inhibitors1. , 1990, , 80-84.		0
90	Heparin released platelet factor 4 in uncomplicated type 1 diabetes mellitus. <i>Thrombosis Research</i> , 1991, 62, 603-604.	1.7	0

#	ARTICLE	IF	CITATIONS
91	The Release of Tissue Factor Pathway Inhibitor and Platelet Factor 4 After Heparin Injection in Patients with Thrombocytosis. Hematology, 1997, 2, 235-241.	1.5	0
92	Recent Advances in the Field of High Affinity IgE Receptors: the Connection to Signal Transduction. , 1993, , 435-440.		0
93	Ubiquitin and ubiquitin-like modifiers modulate NK cell-mediated recognition and killing of damaged cells. AIMS Allergy and Immunology, 2017, 1, 164-180.	0.5	0